{"title":"Differential optimal follicle sizes for ovulatory dysfunction and unexplained infertility in LE-IUI cycles: a retrospective analysis.","authors":"Yihua Liang, Haiyan Lin, Qi Qiu, Ping Pan, Xuedan Jiao, Yu Li, Qingxue Zhang","doi":"10.1186/s40001-025-02372-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aims to identify the optimal dominant follicle size on the trigger day in patients with ovulatory dysfunction and unexplained infertility undergoing intrauterine insemination with letrozole (LE-IUI) cycles.</p><p><strong>Methods: </strong>A retrospective analysis included 411 cycles of each group after 1:1 propensity score matching, comparing basic characteristics and outcomes based on dominant follicle size.</p><p><strong>Results: </strong>Higher rates of HCG positive, clinical pregnancy, and live birth were found in ovulatory dysfunction versus unexplained infertility (22.4% vs. 9.5%; 21.5% vs. 7.9%; 19% vs. 7.1%, P < 0.001). In ovulatory dysfunction, dominant follicles 17-18.9 mm had lower rates of HCG positive (7.6% vs. 21.5% vs. 26.2%, P = 0.007), clinical pregnancy (6.1% vs. 21.5% vs. 25.6%, P = 0.004), and live birth (4.5% vs. 19.2% vs. 23.2%, P = 0.004) compared to 19-21.0 mm and > 21.0 mm groups. Conversely, in unexplained infertility, follicles > 21.0 mm had lower HCG positive rate(13.3% vs. 11.8% vs. 3.4%, P = 0.023) compare to other two groups. Dominant follicle size on trigger day influenced HCG positive rate in LE-IUI cycles for both groups.</p><p><strong>Conclusion: </strong>Triggering at follicle size ≥ 19.0 mm may be optimal for ovulatory dysfunction, while a size ≤ 21 mm may improve HCG positive rates in unexplained infertility, underscoring the need to consider infertility factors in trigger decisions.</p><p><strong>Trial registration: </strong>This study is registered with China Medical Research Online (Registration Number: MR-44-23-038090S, www.medicalresearch.org.cn ).</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"150"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877680/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-02372-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This study aims to identify the optimal dominant follicle size on the trigger day in patients with ovulatory dysfunction and unexplained infertility undergoing intrauterine insemination with letrozole (LE-IUI) cycles.
Methods: A retrospective analysis included 411 cycles of each group after 1:1 propensity score matching, comparing basic characteristics and outcomes based on dominant follicle size.
Results: Higher rates of HCG positive, clinical pregnancy, and live birth were found in ovulatory dysfunction versus unexplained infertility (22.4% vs. 9.5%; 21.5% vs. 7.9%; 19% vs. 7.1%, P < 0.001). In ovulatory dysfunction, dominant follicles 17-18.9 mm had lower rates of HCG positive (7.6% vs. 21.5% vs. 26.2%, P = 0.007), clinical pregnancy (6.1% vs. 21.5% vs. 25.6%, P = 0.004), and live birth (4.5% vs. 19.2% vs. 23.2%, P = 0.004) compared to 19-21.0 mm and > 21.0 mm groups. Conversely, in unexplained infertility, follicles > 21.0 mm had lower HCG positive rate(13.3% vs. 11.8% vs. 3.4%, P = 0.023) compare to other two groups. Dominant follicle size on trigger day influenced HCG positive rate in LE-IUI cycles for both groups.
Conclusion: Triggering at follicle size ≥ 19.0 mm may be optimal for ovulatory dysfunction, while a size ≤ 21 mm may improve HCG positive rates in unexplained infertility, underscoring the need to consider infertility factors in trigger decisions.
Trial registration: This study is registered with China Medical Research Online (Registration Number: MR-44-23-038090S, www.medicalresearch.org.cn ).
背景:本研究旨在确定排卵功能障碍和不明原因不孕症患者接受来曲唑(LE-IUI)周期宫内人工授精时触发日的最佳优势卵泡大小。方法:回顾性分析各组411个周期,经1:1倾向评分匹配,比较优势卵泡大小的基本特征和结果。结果:与原因不明的不孕症相比,排卵功能障碍患者HCG阳性、临床妊娠和活产率更高(22.4% vs 9.5%;21.5% vs. 7.9%;19% vs. 7.1%, P 21.0 mm组。相反,在原因不明的不孕症中,卵泡直径21.0 mm的HCG阳性率低于其他两组(13.3% vs. 11.8% vs. 3.4%, P = 0.023)。触发日优势卵泡大小影响两组LE-IUI周期HCG阳性率。结论:卵泡大小≥19.0 mm可能是排卵功能障碍的最佳触发点,而卵泡大小≤21 mm可能提高不明原因不孕症的HCG阳性率,这强调了在决定触发点时考虑不孕因素的必要性。试验注册:本研究在中国医学研究在线注册(注册号:MR-44-23-038090S, www.medicalresearch.org.cn)。
期刊介绍:
European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.